Alexandria Real Estate Equities has been one of those stocks that quietly broke people. Life sciences offices, lab space, biotech campuses. For years it was the boring blue chip of real estate, the one REIT your financially conservative uncle owned and bragged about. Then it dropped about 75% from its peak and now trades around $51.

The bull case, laid out in a deep dive on Seeking Alpha, is simple: the risk was at $220, not at $51. Sounds like a cute line until you sit with it. It's basically the whole argument for value investing squeezed into one sentence.

So what happened. Life sciences real estate got hit by two things at once. Higher interest rates crushed REIT valuations across the board, and then a wave of lab construction dumped a bunch of new supply right as biotech funding dried up. Tenants stopped expanding. Vacancy crept up. The market looked at all that and priced Alexandria like the business was permanently broken.

But supply responds to pain, and this is the part I find genuinely interesting. New lab construction starts have collapsed. Developers don't break ground on speculative lab buildings when the last tenant they chased signed at a discount. The pipeline that was terrifying everyone in 2024 and 2025 is now getting delivered and absorbed, and behind it there's close to nothing coming. If biotech funding recovers even modestly, tenants are going to walk into a market with way fewer options than they had two years ago.

That's the setup. Falling supply, rents that reset lower but stabilize, and a stock already down 75%.

Now let me be transparent about my own bias here, because that's the deal. I wrote about Piedmont Realty last week, another office-adjacent REIT trading like the sector is terminal, and I said the same thing: office is the sector where "cheap" and "value trap" wear the same outfit. That applies double to Alexandria. The dividend yield here is fat, fat yields on REITs can mean the market thinks a cut is coming, and biotech funding depends on a venture capital cycle nobody can predict. If rates stay high and VC money stays cautious, Alexandria can sit at $51 for another two years while you collect a yield that keeps getting repriced downward.

Warren would tell me to just buy the index fund and stop poking around in damaged REITs. He's probably right, and my automatic monthly buy into broad funds happened this week like always, crash signals and all. But I also think there's a real difference between buying a story at its euphoric peak and buying the same story after a 75% haircut with the supply pipeline emptied out. At $220 you were paying for the dream. At $51 you're paying a price that already assumes a fair amount of bad news actually happens.

The honest framing: this is a turnaround bet with a yield attached, and turnarounds take longer than anyone models. If you want life sciences exposure, treat it like I'd treat any single-sector play. A topping, not the meal. Maybe a small position, maybe wait for the next quarterly report to show vacancy stabilizing before you touch it at all. The supply story only matters if demand shows up, and demand means biotechs getting funded again.

I'm watching two numbers. One, the vacancy trend over the next two quarters. Two, whether the dividend survives intact. If both hold, $51 is going to look like one of those obvious-in-hindsight moments. If either breaks, the market was right to be scared and I was right to keep this small.

Either way, the people who bought at $220 learned an expensive lesson about paying up for consensus. The people staring at $51 have a much more interesting question to answer.